Oral Solid Dosage Contract Manufacturing Market Outlook 2031
The global Oral Solid Dosage Contract Manufacturing market size was USD 31.1 Bn in 2022 and is likely to reach USD 50 Bn by 2031, expanding at a CAGR of 5.6% during 2023–2031. The market growth is attributed to the rising aging population and growing advancements in drug development.
Rising demand for biosimilars and specialized formulations in oral solid dosage forms is anticipated to significantly boost the market. Increasing population and healthcare needs create high healthcare demand leading to a large supply of pharmaceuticals.
Oral solid dosage (OSD) contract manufacturing refers to the outsourcing of the production of pharmaceutical products that are in a solid form intended for oral administration. This includes tablets, capsules, powders, and other similar forms.
The market report finds that the COVID-19 pandemic affected the oral solid dosage contract manufacturing market. The pandemic led to disruptions in global supply chains due to lockdowns, travel restrictions, and closures of manufacturing facilities. This affected the sourcing of raw materials, packaging materials, and other essential components required for OSD production.
The pandemic surged the demand for specific medications such as those used to treat COVID-19 symptoms and related conditions. This increased the production of oral solid dosage forms, putting pressure on contract manufacturers to extend production quickly.
Oral Solid Dosage Contract Manufacturing Market Dynamics
Major Drivers
Increasing demand for pharmaceuticals drives the oral solid dosage contract manufacturing market. The global population is increasing, which leads to a rising geriatric population, they have a high need for pharmaceutical interventions to manage chronic health conditions. Rising incidences of chronic diseases such as cardiovascular diseases, diabetes, and respiratory disorders often require long-term medication, which increases the demand for oral solid dosage forms. For instance,
Existing Restraints
Regulatory compliance and quality assurance hampers the market. The pharmaceutical industry is highly regulated and contract manufacturers need to follow a range of standards including good manufacturing practices (GMP) is costly. They require substantial investments in training, equipment, and documentation, which increases operational costs for contract manufacturers.
Emerging Opportunities
Growing adoption of advanced manufacturing technologies (AMTs) creates lucrative opportunities for the market. Adoption of advanced manufacturing technologies such as continuous manufacturing and 3D printing can enhance efficiency and flexibility in OSD production. AMTs often integrate advanced quality control systems including real-time monitoring and analytics. This leads to high product quality, which complies with regulatory standards by improving overall customer satisfaction.
Scope of the Oral Solid Dosage Contract Manufacturing Market Report
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Oral Solid Dosage Contract Manufacturing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Product Type (Powder, Granule, Tablets, and Capsules), Mechanism (Controlled-release, Delayed-release, and Immediate-release), and End-user (Large-Size Companies and Medium- & Small-Size Companies)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Aenova Holding GmbH; AbbVie Inc.; Boehringer Ingelheim International GmbH; CordenPharma International; Catalent, Inc; Jubilant Pharma Limited; Lonza; NextPharma Technologies; Piramal Pharma Solutions; Recipharm AB; Siegfried Holding AG; and Thermo Fisher Scientific Inc.
|
Market Segment Insights
Product Type Segment Analysis
Based on product type, the oral solid dosage contract manufacturing market is divided into powder, granule, tablets, and capsules. The tablet segment holds segment is expected to hold a dominant share of the market during the projection period, due to it providing ease of administration and offering diverse formulations.
Tablets are one of the highly preferred oral dosage forms among patients. They are easy to swallow, convenient to carry, and have a longer shelf life as compared to other dosage forms. Tablets offer flexibility in formulation design. They can be formulated in various ways including immediate-release, extended-release, and controlled-release formulations. This versatility allows pharmaceutical manufacturers to cater to a wide range of patient needs and therapeutic requirements.
The capsules segment is expected to expand at a significant pace in the coming years, as it provides improved bioavailability and reduced disintegration time. Capsules often provide superior bioavailability for certain drugs compared to tablets, as they can contain a wide range of formulations including powders, granules, or even liquids. Capsules are disintegrated more quickly in the digestive system as compared to tablets. This leads to faster absorption of the active ingredient, which is beneficial for drugs that require rapid onset of action.
Mechanism Segment Analysis
On the basis of mechanism, the global market is segregated into controlled-release, delayed-release, and immediate-release. The controlled-released segment is projected to register a high CAGR during the forecast period due to increasing demand for long-acting formulation and the fluctuation in plasma levels.
Growing demand for medications that offer prolonged therapeutic effects, which allows for less frequent dosing. Controlled-release formulations fulfill this need by releasing the active ingredient gradually over an extended period, resulting in reduced dosing frequency. Controlled-release mechanisms help maintain a consistent concentration of the active ingredient in the body. This minimizes fluctuations in drug plasma levels, which reduces side-effects and eases the therapeutic experience for patients.
End-user Segment Analysis
On the basis of end-user, the oral solid dosage contract manufacturing market is segmented into large-size companies and medium- & small-size companies. The large-size companies segment is anticipated to register a robust growth rate during the forecast period due to economies of scale and it provides a diverse product portfolio.
Large pharmaceutical companies often have the financial resources to invest in advanced manufacturing facilities and technologies. This enables them to achieve economies of scale by producing OSD products in high volumes, which leads to cost savings. Large-size companies typically have a diverse portfolio of products across various therapeutic areas. This necessitates a wide range of OSD formulations that can be efficiently produced by specialized contract manufacturers.
The medium- & small-size companies segment is expected to expand at a significant growth rate in the coming years, due to outsourcing for cost-efficiency and focus on core competencies. Medium- and small-size companies often have limited resources and do not have the capital to invest in their own manufacturing facilities. They outsource OSD production and reduce capital expenditure, operational costs, and overhead expenses associated with in-house manufacturing.
They prioritize activities such as R&D and marketing and choose to partner with specialized contract manufacturers for the production of OSD products. This allows them to allocate resources strategically and focus on their areas of expertise.
Regional Outlook
In terms of region, the global oral solid dosage contract manufacturing market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Asia Pacific is expected to dominate the market during the projection period due to region provides a cost-effective solution and strong manufacturing infrastructure.
Emerging economies within Asia Pacific, particularly India and China, are known for offering cost-effective solutions in OSD contract manufacturing. This cost advantage is a significant driver for pharmaceutical companies looking to optimize their production expenses. Asia Pacific has a well-established and robust manufacturing infrastructure, with advanced facilities equipped to handle OSD production on a large scale. This infrastructure supports efficient and streamlined manufacturing processes. For instance,
-
In June 2020, Piramal Enterprises Ltd. acquired G&W Laboratories Inc.’s oral solid dosage drug manufacturing facility in Sellersville, Pennsylvania, in the US. This acquisition significantly increased Piramal Pharma Solutions’ (PPS) presence in North America by enriching its offerings with enhanced capabilities in producing oral solid dosage forms, encompassing tablets and capsules.
The market in North America is projected to grow rapidly during the forecast period, owing to the advanced healthcare infrastructure and stringent regulatory standards. North America boasts a highly developed and sophisticated healthcare infrastructure. This includes advanced manufacturing facilities, research institutions, and regulatory agencies, providing a favorable environment for OSD contract manufacturing. North America has a strict regulatory environment that ensures products manufactured in the region meet rigorous quality and safety requirements.
Segments
The oral solid dosage contract manufacturing market has been segmented on the basis of
Product Type
- Powder
- Granule
- Tablets
- Capsules
Mechanism
- Controlled-release
- Delayed-release
- Immediate-release
End-user
- Large-Size Companies
- Medium- & Small-Size Companies
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the global oral solid dosage contract manufacturing market are Aenova Holding GmbH; AbbVie Inc.; Boehringer Ingelheim International GmbH; CordenPharma International; Catalent, Inc; Jubilant Pharma Limited; Lonza; NextPharma Technologies; Piramal Pharma Solutions; Recipharm AB; Siegfried Holding AG; and Thermo Fisher Scientific Inc.
These companies adopt development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production expansion to expand their consumer base worldwide. For instance,
-
In February 2022, Corden Pharma announced the acquisition of three manufacturing facilities belonging to Vifor Pharma. This strategic move is set to substantially strengthen Corden Pharma's capacities and expertise in the production of Oral Solid Dosage (OSD) forms including capsules and tablets, along with non-sterile drug product dosage forms.
Request For Customization
Enquiry Before Buying
Speak With Analyst
